BioTrinity 2022 is only a couple weeks away! Medicilon is excited to attend and exhibit at the conference. Our Vice President and Business Development team will be exhibiting at the conference. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!

BioTrinity 2022 集行業之聲，讓中國醫藥界感知 BioTrinity 的新訊息。美迪西很高興能參加此次BioTrinity 。我們歐洲團隊將出席此次會議。我們期待與您會面并討論美迪西的強大服務能力將如何支持您的研發需求，并加快您的藥物研發！

Date: April 26-27, 2022

Location: England, United Kingdom

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

? 這是一次生命科學行業的面對面深度會談。參加此次活動的有早期和新興生命科學研發公司、投資者、大型制藥公司和整個生命科學生態系統中的其他重要合作伙伴。江山代有人才出，由眾多的優秀演講者帶來新技術的分享！

? 七個核心治療領域——腫瘤學、中樞神經系統、微生物組、炎癥、罕見病、傳染病以及人工智能和數據。

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance.Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

Innovative Drug R&D Services

美迪西深度整合研發經驗，不斷攀登研發技術高峰，搭建新藥研發一體化創新服務平臺：

? ADC臨床前研發項目
? PROTAC 藥物發現技術平臺
? mRNA疫苗生物分析技術平臺
? 細胞免疫治療藥物平臺等